Tumor burden in patients with early and intermediate-stage hepatocellular carcinoma undergoing liver resection: a retrospective multicenter study on clinical and oncological outcomes.

Details

Ressource 1Request a copy Under indefinite embargo.
UNIL restricted access
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_44930D196958
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Tumor burden in patients with early and intermediate-stage hepatocellular carcinoma undergoing liver resection: a retrospective multicenter study on clinical and oncological outcomes.
Journal
HPB
Author(s)
Martin D., Smet H., Da Silva Costa A.C., Halkic N., Uldry E., Tabrizian P., Schwartz M., Mahamid A., Goumard C., Scatton O., Perinel J., Adham M., Demartines N., Melloul E.
ISSN
1477-2574 (Electronic)
ISSN-L
1365-182X
Publication state
Published
Issued date
07/2023
Peer-reviewed
Oui
Volume
25
Number
7
Pages
836-844
Language
english
Notes
Publication types: Multicenter Study ; Journal Article
Publication Status: ppublish
Abstract
According to the Barcelona Clinic Liver Cancer (BCLC) staging system, liver resection (LR) is recommended for early-stage (BCLC-A) hepatocellular carcinoma (HCC) but not for intermediate-stage (BCLC-B). This study aimed to assess the outcomes of LR in these patients using a subclassification tumour burden score (TBS).
All consecutive patients that underwent LR for BCLC-A and BCLC-B HCC between 01/2010 and 12/2020 in 4 tertiary referral centers were included. Clinical outcomes and overall survival (OS) were assessed in relation to TBS and BCLC stages.
Among 612 patients included, 562 were classified as BCLC-A and 50 as BCLC-B. The incidence of overall postoperative complications (56.0 vs 41.5%, p = 0.053) and mortality (0 vs 1.6%, p = 1.000) were similar between BCLC-A and BCLC-B patients. OS was significantly higher for BCLC A/low TBS than BCLC B/low TBS (p = 0.009), while patients with medium and high TBS had similar OS, irrespective of BCLC stage (respectively p = 0.103 and p = 0.343).
Patients with medium and high TBS had comparable OS and DFS, irrespective of BCLC A or B stage, and postoperative morbidity was comparable. These results highlight the need for refinement of the BCLC staging system, and LR could be considered for selected intermediate stage (BCLC-B) according to the tumour burden.
Keywords
Humans, Carcinoma, Hepatocellular, Liver Neoplasms, Tumor Burden, Neoplasm Staging, Retrospective Studies, Hepatectomy/adverse effects
Pubmed
Web of science
Create date
29/04/2023 13:38
Last modification date
01/08/2023 5:56
Usage data